Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 3/2017

Open Access 14.09.2016 | Retinal Disorders

Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study

verfasst von: Joo Eun Lee, Jae Pil Shin, Hyun Woong Kim, Woohyok Chang, Yu Cheol Kim, Sang Joon Lee, In Young Chung, Ji Eun Lee, VAULT study group

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy (PCV).

Methods

This phase IV, prospective, single-arm, interventional case series was conducted in eight centers. Forty treatment-naïve PCV patients were administered three monthly doses of intravitreal aflibercept (2.0 mg) and an injection every 2 months thereafter. Best-corrected visual acuity (BCVA) and central subfield macular thickness (CSMT) were measured at each visit. Fluorescein and indocyanine green angiography (ICGA) were performed at baseline, 3 and 12 months. The primary outcome measure was the proportion of patients who maintained BCVA (<15 letters loss) at 12 months. Changes in BCVA, macular appearance, and polypoidal lesion appearance were also examined.

Results

Thirty-five eyes (87.5 %) had maintained BCVA at 12 months. Average BCVA was significantly higher at 12 months (20/53, 64.2 letters) than at baseline (20/80, 55.1 letters, 9-letter gain; P < .001). Mean CSMT was significantly lower at 12 months (253.6 μm) than at baseline (365.2 μm, P < .001). The macula was dry in 32 (76.2 %), 27 (64.3 %), and 24 eyes (60.0 %) at 3, 6, and 12 months respectively. Fourteen eyes (33.3 %) had a fluid recurrence or increase at 6 months, and they had a significantly lower vision gain (P = .005) than other patients at 12 months. Complete polyp regression occurred in 26 eyes (66.7 %) at 12 months.

Conclusions

Fixed-dosing aflibercept showed favorable outcomes in PCV patients at 12 months. However, some patients had worse outcomes because of fluid recurrence during maintenance dosing, and these patients would require additional treatments.
Literatur
1.
Zurück zum Zitat Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ (2000) Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 238:752–759CrossRefPubMed Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ (2000) Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 238:752–759CrossRefPubMed
2.
Zurück zum Zitat Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed
3.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMed Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMed
4.
Zurück zum Zitat Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRefPubMed Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRefPubMed
5.
Zurück zum Zitat Gomi F, Sawa M, Sakaguchi H, Sasamoto Y, Suzuki M, Tzujikawa M (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73CrossRefPubMed Gomi F, Sawa M, Sakaguchi H, Sasamoto Y, Suzuki M, Tzujikawa M (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73CrossRefPubMed
6.
Zurück zum Zitat Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94:297–301CrossRefPubMed Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94:297–301CrossRefPubMed
7.
Zurück zum Zitat Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N (2010) Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 54:310–319CrossRefPubMed Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N (2010) Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 54:310–319CrossRefPubMed
8.
Zurück zum Zitat Koh A, Lee WK, Chen LJ et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453–1464CrossRefPubMed Koh A, Lee WK, Chen LJ et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453–1464CrossRefPubMed
9.
Zurück zum Zitat Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y (2007) Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 245:1569–1571CrossRefPubMed Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y (2007) Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 245:1569–1571CrossRefPubMed
10.
Zurück zum Zitat Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H (2009) Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 29:960–965CrossRefPubMed Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H (2009) Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 29:960–965CrossRefPubMed
11.
Zurück zum Zitat Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye (Lond) 27:1013–1020CrossRef Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye (Lond) 27:1013–1020CrossRef
12.
Zurück zum Zitat Oishi A, Kojima H, Mandai M et al (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644–651CrossRefPubMed Oishi A, Kojima H, Mandai M et al (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644–651CrossRefPubMed
13.
Zurück zum Zitat Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548CrossRefPubMed Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548CrossRefPubMed
14.
Zurück zum Zitat Hosokawa M, Shiraga F, Yamashita A et al (2015) Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol 99:1087–1091CrossRefPubMed Hosokawa M, Shiraga F, Yamashita A et al (2015) Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol 99:1087–1091CrossRefPubMed
15.
Zurück zum Zitat Inoue M, Arakawa A, Yamane S, Kadonosono K (2014) Short-term efficacy of intravitreal aflibercept in treatment-naïve patients with polypoidal choroidal vasculopathy. Retina 34:2178–2184CrossRefPubMed Inoue M, Arakawa A, Yamane S, Kadonosono K (2014) Short-term efficacy of intravitreal aflibercept in treatment-naïve patients with polypoidal choroidal vasculopathy. Retina 34:2178–2184CrossRefPubMed
16.
Zurück zum Zitat Oishi A, Tsujikawa A, Yamashiro K et al (2015) One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol 159:853–860CrossRefPubMed Oishi A, Tsujikawa A, Yamashiro K et al (2015) One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol 159:853–860CrossRefPubMed
17.
Zurück zum Zitat Yamamoto A, Okada AA, Kano M et al (2015) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866–1872CrossRefPubMed Yamamoto A, Okada AA, Kano M et al (2015) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866–1872CrossRefPubMed
18.
Zurück zum Zitat Koh AH, Chen LJ, Chen SJ et al (2013) Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 33:686–716CrossRefPubMed Koh AH, Chen LJ, Chen SJ et al (2013) Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 33:686–716CrossRefPubMed
19.
Zurück zum Zitat Byon IS, Kwon HJ, Kim SI, Shin MK, Park SW, Lee JE (2014) Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab. Ophthalmic Surg Lasers Imaging Retina 45:534–541CrossRefPubMed Byon IS, Kwon HJ, Kim SI, Shin MK, Park SW, Lee JE (2014) Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab. Ophthalmic Surg Lasers Imaging Retina 45:534–541CrossRefPubMed
20.
Zurück zum Zitat Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393–11398CrossRefPubMedPubMedCentral Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393–11398CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentral Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentral
Metadaten
Titel
Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study
verfasst von
Joo Eun Lee
Jae Pil Shin
Hyun Woong Kim
Woohyok Chang
Yu Cheol Kim
Sang Joon Lee
In Young Chung
Ji Eun Lee
VAULT study group
Publikationsdatum
14.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 3/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3489-5

Weitere Artikel der Ausgabe 3/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.